Bibliography: Substance-Related and Addictive Disorders

Volkow ND, Baler RD: Addiction science: uncovering neurobiological complexity. Neuropharmacology 2014 Jan;76 Pt B:235–249Crossref, Google Scholar

Belcher AM, Volkow ND, Moeller FG, et al.: Personality traits and vulnerability or resilience to substance use disorders. Trends Cogn Sci 2014; 18:211–217Crossref, Google Scholar

Chiesa A, Serretti A: Are mindfulness-based interventions effective for substance use disorders? A systematic review of the evidence. Subst Use Misuse 2014; 49:492–512Crossref, Google Scholar

Everitt BJ: Neural and psychological mechanisms underlying compulsive drug seeking habits and drug memories—indications for novel treatments of addiction. Eur J Neurosci 2014; 40:2163–2182Crossref, Google Scholar

Wise RA, Koob GF: The development and maintenance of drug addiction. Neuropsychopharmacology 2014; 39:254–262Crossref, Google Scholar

Pettinati HM, O’Brien CP, Dundon WD: Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry 2013; 170:23–30Google Scholar

Volkow ND, Wang GJ, Tomasi D, et al.: The addictive dimensionality of obesity. Biol Psychiatry 2013; 73:811–818Crossref, Google Scholar

Volkow ND, Wang GJ, Fowler JS, et al: Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol 2012; 52:321–336Google Scholar

Koob GF, Volkow ND: Neurocircuitry of addiction. Neuropsychopharmacology 2010; 35:217–238Crossref, Google Scholar

Soyka M: New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone. Subst Abuse Rehabil 2015; 6:1–14Crossref, Google Scholar

Fullerton CA, Kim M, Thomas CP, et al.: Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv 2014; 65:146–157Link, Google Scholar

Mattick RP, Breen C, Kimber J, et al.: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; 2:CD002207Google Scholar

Nuckols TK, Anderson L, Popescu I, et al.: Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med 2014; 160:38–47Google Scholar

Thomas CP, Fullerton CA, Kim M, et al: Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv 2014; 65:158–170Google Scholar

Centers for Disease Control and Prevention: Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR Morb Mortal Wkly Rep 2011; 60:1487–1492Google Scholar

Institute of Medicine Committee on Advancing Pain Research Care and Education: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC, National Academies Press, 2011Google Scholar

Turk DC, Wilson HD, Cahana A: Treatment of chronic non-cancer pain. Lancet 2011; 377:2226–2235Crossref, Google Scholar

Stotts AL, Dodrill CL, Kosten TR: Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother 2009; 10:1727–1740Crossref, Google Scholar

Volkow ND, Baler RD, Compton WM, et al.: Adverse health effects of marijuana use. N Engl J Med 2014; 370:2219–2227Crossref, Google Scholar

Pertwee RG: Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci 2012; 367:3353–3363Crossref, Google Scholar

Fraser GA: The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther 2009; 15:84–88Crossref, Google Scholar

Leweke FM, Giuffrida A, Koethe D, et al.: Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res 2007; 94:29–36Crossref, Google Scholar

Kathuria S, Gaetani S, Fegley D, et al.: Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003; 9:76–81Crossref, Google Scholar

Piomelli D: The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003; 4:873–884Crossref, Google Scholar

Ilieva IP, Hook CJ, Farah MJ: Prescription stimulants' effects on healthy inhibitory control, working memory, and episodic memory: a meta-analysis. J Cogn Neurosci 2015; 27:1069–1089Crossref, Google Scholar

Coghill DR, Seth S, Pedroso S, et al.: Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis. Biol Psychiatry 2014; 76:603–615Crossref, Google Scholar

Franke AG, Bagusat C, Rust S, et al.: Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects. Eur Arch Psychiatry Clin Neurosci 2014; 264(Suppl 1):S83–S90Crossref, Google Scholar

Kosten TR, Domingo CB, Shorter D, et al.: Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. Drug Alcohol Depend 2014; 140:42–47Crossref, Google Scholar

Kosten TR, Wu G, Huang W, et al.: Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase. Biol Psychiatry 2013; 73:219–224Crossref, Google Scholar

Morente-Sánchez J, Zabala M: Doping in sport: a review of elite athletes’ attitudes, beliefs, and knowledge. Sports Med 2013; 43:395–411Crossref, Google Scholar

Weyandt LL, Marraccini ME, Gudmundsdottir BG, et al.: Misuse of prescription stimulants among college students: a review of the literature and implications for morphological and cognitive effects on brain functioning. Exp Clin Psychopharmacol 2013; 21:385–407Crossref, Google Scholar

Boghosian T, Mazzoni I, Barroso O, et al.: Investigating the use of stimulants in out-of-competition sport samples. J Anal Toxicol 2011; 35:613–616Crossref, Google Scholar

Sahakian BJ, Morein-Zamir S: Neuroethical issues in cognitive enhancement. J Psychopharmacol 2011; 25:197–204Google Scholar

Cavazos-Rehg PA, Breslau N, Hatsukami D, et al.: Smoking cessation is associated with lower rates of mood/anxiety and alcohol use disorders. Psychol Med 2014; 44:2523–2535Crossref, Google Scholar

Prochaska JJ, Hall SE, Delucchi K, et al.: Efficacy of initiating tobacco dependence treatment in inpatient psychiatry: a randomized controlled trial. Am J Public Health 2014; 104:1557–1565Crossref, Google Scholar

Shahab L, Andrew S, West R: Changes in prevalence of depression and anxiety following smoking cessation: results from an international cohort study (ATTEMPT). Psychol Med 2014; 44:127–141Google Scholar

Taylor G, McNeill A, Girling A, et al.: Change in mental health after smoking cessation: systematic review and meta-analysis. BMJ 2014; 348:g1151Crossref, Google Scholar

Khaled SM, Bulloch AG, Williams JV, et al.: Persistent heavy smoking as risk factor for major depression (MD) incidence—evidence from a longitudinal Canadian cohort of the National Population Health Survey. J Psychiatr Res 2012; 46:436–443Crossref, Google Scholar

McFall M, Saxon AJ, Malte CA, et al.; CSP 519 Study Team: Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trial. JAMA 2010; 304:2485–2493Crossref, Google Scholar

Ziedonis D, Hitsman B, Beckham JC, et al.: Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res 2008; 10:1691–1715Crossref, Google Scholar

Day E, Copello A, Hull M: Assessment and management of alcohol use disorders. BMJ 2015; 350:h715Crossref, Google Scholar

Koob GF: Alcohol use disorders: tracts, twins, and trajectories. Am J Psychiatry 2015; 172:499–501Google Scholar

O’Brien C: In treating alcohol use disorders, why not use evidence-based treatment? Am J Psychiatry 2015; 172:305–306Google Scholar

Substance Abuse and Mental Health Services Administration and National Institute on Alcohol Abuse and Alcoholism: Medication for the Treatment of Alcohol Use Disorder: A Brief Guide. HHS Publication No. (SMA) 15-4907. Rockville, MD, Substance Abuse and Mental Health Services Administration, 2015Google Scholar

Enoch MA: Genetic influences on response to alcohol and response to pharmacotherapies for alcoholism. Pharmacol Biochem Behav 2014; 123:17–24Crossref, Google Scholar

Galanter M: Alcoholics Anonymous and twelve-step recovery: a model based on social and cognitive neuroscience. Am J Addict 2014; 23:300–307Crossref, Google Scholar

Gelernter J, Kranzler HR, Sherva R, et al.: Genome-wide association study of alcohol dependence: significant findings in African- and European-Americans including novel risk loci. Mol Psychiatry 2014; 19:41–49Crossref, Google Scholar

Jonas DE, Amick HR, Feltner C, et al.: Pharmacotherapy for Adults with Alcohol-Use Disorders in Outpatient Settings. Comparative Effectiveness Review No. 134. AHRQ Publication No. 14-EHC029-EF. Rockville, MD, Agency for Healthcare Research and Quality, 2014. Available at effectivehealthcare.ahrq.gov/ehc/products/477/1908/alcohol-misuse-drug-therapy-report-140513.pdfGoogle Scholar

Klimas J, Tobin H, Field CA, et al.: Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users. Cochrane Database Syst Rev 2014; 12:CD009269Google Scholar

Lenaerts E, Matheï C, Matthys F, et al.: Continuing care for patients with alcohol use disorders: a systematic review. Drug Alcohol Depend 2014; 135:9–21Crossref, Google Scholar

Maisel NC, Blodgett JC, Wilbourne PL, et al.: Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 2013; 108:275–293Crossref, Google Scholar